Pfizer price target raised to $28 from $27 at BofA

BofA raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps a Neutral rating on the shares following Q2 results that were “solid across the board” along with 2025 revenue guidance being maintained and EPS guidance raised “slightly.” The firm’s new reflects a lower multiple being applied to its underlying 2026 EPS forecast, telling investors that the new multiple reflects Pfizer’s below average earnings growth trajectory relative to peers.